US FDA Collates GMP Data Integrity Advice Into New Guidance
This article was originally published in SRA
Executive Summary
Some questions and answers about data integrity that the US Food and Drug Administration published April 14 as draft guidance could go a long way toward helping drug manufacturers avoid the type of import alerts and warning letters that in recent years have come to dominate the agency's drug good manufacturing practices enforcement activities1,2.